Morgan Stanley lowered the firm’s price target on Cytek Biosciences (CTKB) to $4 from $7 and keeps an Equal Weight rating on the shares post the Q2 report. The firm says recurring revenue strength offset weakness in the company’s instrument segment. It believes Cytek’s visibility remains limited.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CTKB:
- Cytek Biosciences Earnings Call Reveals Mixed Outlook
- Cytek Biosciences: Q2 2025 Financial Performance Overview
- Cytek Biosciences Faces Market Challenges and Uncertain Growth Prospects Leading to Hold Rating
- Cytek Biosciences reports Q2 EPS (4c), consensus (1c)
- Cytek Biosciences narrows FY25 revenue view to $196M-$200M from $196M-$210M